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Introduction {#onco13304-sec-0005}
============

Cancer has long been categorized and treated based on its anatomic origin and localization. However, with the development of clinically available and robust comprehensive genomic sequencing assays, genomic driver alterations that are involved in the tumor development and progression could be detected and allow personalized therapies of actionable gene alterations.

*NTRK* gene fusions represent one of the most important molecular changes with known oncogenic and transforming potential [1](#onco13304-bib-0001){ref-type="ref"}. Gene fusions lead to transcription of chimeric TRK oncoproteins that are constitutively active and serve as oncogenic drivers in a wide variety of cancers. Therefore, *NTRK* gene fusions are currently being investigated in several tumor types as targets for cancer therapy [2](#onco13304-bib-0002){ref-type="ref"}.

Regarding a treatment of *NTRK* gene fusions, several TRK inhibitors have been developed, including larotrectinib. Larotrectinib is an orally available selective inhibitor of the TRK receptor family that has shown significant clinical benefit in pediatric and adult patients with *NTRK* gene fusion in recent years and is now approved in the European Union (EU) and the U.S. [3](#onco13304-bib-0003){ref-type="ref"}, [4](#onco13304-bib-0004){ref-type="ref"}. *NTRK* gene amplification has shown to result in TRK overexpression as well [5](#onco13304-bib-0005){ref-type="ref"}. However, knowledge on the efficacy of targeted therapy for *NTRK* gene amplification is yet rare. To our knowledge, there has been only one patient described so far who harbored an *NTRK1* gene amplification and who had a partial response after treatment with larotrectinib [6](#onco13304-bib-0006){ref-type="ref"}. This patient was described in a multicenter, open‐label, phase I dose‐escalation study, which investigated larotrectinib in adult patients with solid tumors [6](#onco13304-bib-0006){ref-type="ref"}.

Esophageal cancer remains a major cause of cancer‐related mortality worldwide and is associated with a poor prognosis in both the locally advanced and metastatic setting [7](#onco13304-bib-0007){ref-type="ref"}, [8](#onco13304-bib-0008){ref-type="ref"}. The majority of patients with esophageal cancer suffer from the metastatic disease at the time of diagnosis or relapse after surgery or chemotherapy [9](#onco13304-bib-0009){ref-type="ref"}. Esophageal cancer includes two main subtypes: oesophageal squamous cell carcinoma and oesophageal adenocarcinoma [10](#onco13304-bib-0010){ref-type="ref"}. The standard therapy for patients with advanced/metastatic squamous cell carcinoma of the esophagus is palliative chemotherapy, usually consisting of cisplatin and a fluropyrimidine. The aim of this therapy is solely to improve the quality of life [11](#onco13304-bib-0011){ref-type="ref"}, [12](#onco13304-bib-0012){ref-type="ref"}. Although this therapy has a life‐prolonging effect in adenocarcinoma, the effect of treatment in squamous cell carcinoma is not assured [12](#onco13304-bib-0012){ref-type="ref"}. The efficacy of targeted therapies has so far only been shown for adenocarcinoma of the esophagus [12](#onco13304-bib-0012){ref-type="ref"}.

In this case report, we present the case of a patient with metastatic squamous cell esophageal carcinoma with *NTRK1* gene amplification who received targeted therapy with larotrectinib. In a search of 879 cases with squamous cell carcinoma of the esophagus identified in the Foundation Medicine database, *NTRK1* fusions were detected in none and gene amplification in two cases (0.2%). Therefore, this case report is of outstanding relevance. Furthermore, to our knowledge, this is merely the second published case of a patient with *NTRK* gene amplification who received larotrectinib.

Clinical Presentation {#onco13304-sec-0006}
=====================

The patient was a 71‐year‐old male who presented in December 2018 at the Oncology Center with dysphagia, dyspnea, cough, swallowing disorders, and weight loss of 20 kg within 3 months. The patient was in a poor general condition with Eastern Cooperative Oncology Group (ECOG) performance status of 3 and had no other pre‐existing conditions. He did not consume alcohol or nicotine and had no previous tumors. Esophagogastroduodenoscopy showed a stenosing esophageal carcinoma in the middle third of the esophagus with an extension of 10--21 cm from the upper row of teeth. Computed tomography (CT) showed bilateral lung metastases, and contrast‐enhanced abdominal ultrasound sonography and CT showed multiple liver metastases. A tumor biopsy from the esophagus and a sonographically controlled liver biopsy were performed to confirm the diagnosis. The results confirmed the diagnosis of both a squamous cell carcinoma of the esophagus and liver metastases consistent with esophageal origin (Fig. [1](#onco13304-fig-0001){ref-type="fig"}). Because of swallowing disorders and stenosis, an esophageal stent was implanted on February 10, 2019 (Fig. [2](#onco13304-fig-0002){ref-type="fig"}).

![Tumor histology. Hematoxylin and eosin staining showed a solid nodular tumor mass in the liver (**A**; --- 100 μm) with a brown‐colored desmoplastic collagen reaction (**B**; --- 100 μm) using the Gomori staining. Immunohistochemistry showed a strong positivity for CK5 and p63 (**C** and **D**; --- 200 μm) to sustain a squamous differentiation of the metastasis. There was a prominent proliferation marked by Ki‐67 (**E**; --- 200 μm) in tumor formation. Fluorescence in situ hybridization analysis for NTRK 3 showed no translocation (**F**; --- 50 μm)](ONCO-25-e881-g001){#onco13304-fig-0001}

![Esophageal stent before therapy with larotrectinib (left) and 6 weeks after treatment (right).](ONCO-25-e881-g002){#onco13304-fig-0002}

Genotyping Results and Interpretation of the Molecular Results {#onco13304-sec-0007}
==============================================================

FoundationOne CDx Test {#onco13304-sec-0008}
----------------------

Approval for this test, including a waiver of informed consent and a Health Insurance Portability and Accountability Act waiver of authorization, was obtained from the Western Institutional Review Board (Protocol 20152817). Informed consent of the patient was obtained to perform genomic profiling. The DNA was isolated from the histological tumor enrichment and its quality and quantity were further investigated. Subsequently, relevant areas of the genome were further enriched by hybrid capture (Agilent SureSelect custom kit) and examined after ligation of adaptors by next‐generation sequencing (NGS; FoundationOne CDx). FoundationOne CDx is a solid tumor genomic profiling test that detects clinically relevant mutations in cancer‐associated genes and provides a comprehensive molecular tumor profile [13](#onco13304-bib-0013){ref-type="ref"}, [14](#onco13304-bib-0014){ref-type="ref"}, [15](#onco13304-bib-0015){ref-type="ref"}, [16](#onco13304-bib-0016){ref-type="ref"}.

Sequencing Results {#onco13304-sec-0009}
------------------

The conventional histology examination from February 2019 identified a metastatic squamous cell esophageal carcinoma (Fig. [1](#onco13304-fig-0001){ref-type="fig"}). Genomic alterations of *CCND1*, *EGFR*, *MET*, *PIK3CA*, *CCND2*, *CDK6*, *HGF*, *SOX2*, *CCND3*, *CDKN2A/B*, *EPHB4*, *FGF19*, *FGF3*, *FGF4 MCL1*, *NTRK1*, *PIM1*, *TP53*, and *VEGFA* were detectable in the examined tumor tissue (primary tumor and liver) and are summarized below (Table [1](#onco13304-tbl-0001){ref-type="table"}). Among the strongly amplified genes, several showed much higher initial amplification levels than *NTRK1* (*EGFR*, *PIK3CA*, *CCND1*, *FGF19*, *FGF3*, and *FGF4*). The microsatellite status was stable and the tumor mutational burden was classified as intermediate with 10 Muts/Mb. Furthermore, genomic variants of unknown significance were detected but did not have a clinical impact.

###### 

Sequencing results

  Gene variation            Initial liver biopsy 02/19      Second liver biopsy 05/19                                                                         
  ------------------------- ------------------------------- ------------------------------ ---------- ------------------------------------------------------- -----------------
  Microsatellite status     MSS                             MSS                                                                                               
  Tumor mutational burden   **Intermediate (10 mut/1MB)**   **Intermediate (6 mut/1MB)**                                                                      
  Estimated tumor content   35.5%                           40.8%                                                                                             
  **Short variant**                                                                                                                                           
  **Gene**                  **Substitution**                **MAF**                        **Gene**   **Substitution**                                        **MAF**
  TP53                      P278T                           0.42                           TP53       P278T                                                   0.37
  **CNV**                                                                                                                                                     
  **Gene**                  **Alteration**                  **Copy number**                **Gene**   **Alteration**                                          **Copy number**
  CCND1                     Amplification                   40                             CCND1      Amplification                                           21
  EGFR                      Amplification                   126                            EGFR       Amplification                                           65
  MET                       Amplification                   13                             MET        Amplification[a](#onco13304-note-0003){ref-type="fn"}   7
  PIK3CA                    Amplification                   45                             PIK3CA     Amplification                                           20
  CCND2                     Amplification                   8                                                                                                 
  CDK6                      Amplification                   10                             CDK6       Amplification[a](#onco13304-note-0003){ref-type="fn"}   6
  HGF                       Amplification                   13                             HGF        Amplification[a](#onco13304-note-0003){ref-type="fn"}   7
  SOX2                      Amplification                   14                             SOX2       Amplification                                           8
  CCND3                     Amplification                   12                             CCND3      Amplification[a](#onco13304-note-0003){ref-type="fn"}   7
  CDKN2A/B                  Loss                            0                              CDKN2A/B   Loss                                                    0
  EPHB4                     Amplification                   8                                                                                                 
  FGF19                     Amplification                   39                             FGF19      Amplification                                           20
  FGF3                      Amplification                   39                             FGF3       Amplification                                           20
  FGF4                      Amplification                   41                             FGF4       Amplification                                           20
  MCL1                      Amplification                   8                                                                                                 
  **NTRK1**                 **Amplification**               **8**                                                                                             
  PIM1                      Amplification                   14                             PIM1       Amplification                                           8
  VEGFA                     Amplification                   12                             VEGFA      Amplification[a](#onco13304-note-0003){ref-type="fn"}   7

Equivocal.

Abbreviations: CNV, copy number variation; MAF, Mutant Allel Frequency; MSS, microsatellite stable.

A fluorescence in situ hybridization (FISH) assay for *NTRK1*, *2*, and *3* fusions was also performed. FISH confirmed the results of NGS. Specifically, there was an absence of *NTRK* fusions but a presence of an *NTRK1* amplification with a copy number of 8 (Table [1](#onco13304-tbl-0001){ref-type="table"}).

After the failure of larotrectinib in May 2019, a subsequent liver biopsy continued to display strong amplification events in the abovementioned genes. However, the total number of amplicons decreased by half, consistently within the analyzed genes (Table [1](#onco13304-tbl-0001){ref-type="table"}).

Patient Update {#onco13304-sec-0010}
--------------

On February 4, 2019, therapy with larotrectinib was initiated. The patient received a standard dose of 2 × 100 mg larotrectinib orally. Side effects did not occur during treatment. Larotrectinib was not yet approved in the EU when the patient was treated but was imported from the U.S. A spiral CT scan done on January 4, 2019, before the treatment initiation showed multiple lung and liver metastases. Two metastases in the left lung segment I/II and in segment VI and two metastases in liver segment VII were considered target lesions for tumor assessment according to RECIST 1.1. With respect to tumor response, the sum of the longest diameters of target lesions was 67.5 mm at baseline. Several pathologically enlarged pre‐ and paracaval lymph nodes were still present. ECOG performance status improved to 1 and the patient recorded a weight gain of 9 kg. He was able to leave the clinic and continue via self‐care. The pathological follow‐up examination performed on April 17, 2019, by esophagogastroduodenoscopy confirmed the decline of the tumor, as the esophageal re‐biopsy was tumor‐free (Fig. [2](#onco13304-fig-0002){ref-type="fig"}). The duodenal mucosa, the antral mucosa, and the corpus mucosa presented without morphologically detectable pathological findings.

On March 22, 2019, a response assessment was undertaken with a CT of the thorax and abdomen. Compared with the examination carried out on February 4, 2019, there was now improvement of the findings, with regression in size of the multiple pulmonary metastases accompanied by tumor marker (squamous cell carcinoma \[SCC\]) decrease (Figs. [3](#onco13304-fig-0003){ref-type="fig"}, [4](#onco13304-fig-0004){ref-type="fig"}). The sum of the longest diameters of the target lesions decreased to 33 mm, which constitutes a partial response according to RECIST criteria. The pleural effusions had receded.

![Computed tomography of lung (upper panel) and liver (lower panel) before treatment with larotrectinib and 6 weeks later, showing partial remission of liver and lung metastases.](ONCO-25-e881-g003){#onco13304-fig-0003}

![Tumor marker value SCC over time.\
Abbreviation: SCC, squamous cell carcinoma.](ONCO-25-e881-g004){#onco13304-fig-0004}

On May 11, 2019, another CT scan and a liver biopsy with contrast medium--guided ultrasound (SonoVue) were performed as a result of a rise of the tumor marker SCC antigene (Fig. [4](#onco13304-fig-0004){ref-type="fig"}). A progressive disease of liver and lung metastases was observed. Results of the rebiopsy of the liver revealed that the *NTRK1* amplification was now below the limit of detection, which could explain the disease progression. The patient refused conventional chemotherapy. He received crizotinib after approval by his health insurance because of the presence of a *MET* amplification. The treatment resulted in stable disease for another 3 months.

Functional and Clinical Significance of *NTRK* Gene Alterations in Esophageal Cancer {#onco13304-sec-0011}
------------------------------------------------------------------------------------

*NTRK 1*, *NTRK 2*, and *NTRK 3* encode for the transmembrane proteins TRK A, B, and C, respectively. These tropomyosin receptor kinase proteins are expressed in human neuronal tissue and play an important role in the physiology of the development and function of the nervous system [2](#onco13304-bib-0002){ref-type="ref"}.

In numerous malignancies, mutations in *NTRK* gene family have been confirmed, although only fusions, in‐frame deletions, and splice variations have been identified as oncogenic [1](#onco13304-bib-0001){ref-type="ref"}. Very little has been reported about *NTRK* gene alterations in esophageal carcinoma. Considering our findings, *NTRK1* alterations in squamous cell carcinoma occur at an extremely low frequency of 0.2%, as identified in the Foundation Medicine database. In two separate studies describing the frequency of *NTRK* fusions in esophageal carcinoma, there was only one case of *NTRK3* fusion defined within 100 biopsies and, respectively, no *NTRK* fusions among 185 biopsies [17](#onco13304-bib-0017){ref-type="ref"}, [19](#onco13304-bib-0019){ref-type="ref"}. However, despite the low *NTRK* fusion and amplification findings, TRK A was observed to be overexpressed in 9/20 cases of esophagus cancer [18](#onco13304-bib-0018){ref-type="ref"}. Therefore, TRK‐specific protein kinase inhibitors might be considered an appropriate therapy.

Discussion {#onco13304-sec-0012}
==========

With larotrectinib, entrectinib, and selitrectinib (formerly known as LOXO‐195), three TRK inhibitors are either already available or still in clinical development. *NTRK1*, *2*, *and 3* genes fuse with unrelated genes, which results in ligand‐independent activation of the protein kinase domain of the TRK receptor. Whereas the activity of larotrectinib and entrectinib in *NTRK* gene fusions is established, their role on *NTRK* amplification is unclear [3](#onco13304-bib-0003){ref-type="ref"}, [20](#onco13304-bib-0020){ref-type="ref"}, [21](#onco13304-bib-0021){ref-type="ref"}. Nonfusion NTRK alterations, for example, mutation or amplification, have been associated with a lack of response with some *NTRK* inhibitors [2](#onco13304-bib-0002){ref-type="ref"}, but recently, in a multicenter, open‐label, phase I dose‐escalation study investigating larotrectinib in adult patients with solid tumors, one patient harbored an *NTRK1* gene amplification and had a partial response with larotrectinib, which was the rationale for treatment decision. The described patient had a single, small target lesion (11 mm) that shrank by 5 mm (45.5%) and the duration of response was 3.7 months [5](#onco13304-bib-0005){ref-type="ref"}, which is similar to the response outcome observed in our patient. We also found a high amplification of *EGFR* in our sample, and this patient could have been treated with anti‐*EGFR* therapy as well. According to the abovementioned publication, the molecular tumor board decided on a treatment with larotrectinib in this particular case, and we saw a short but significant tumor shrinkage according to RECIST criteria classified as partial remission.

Similar to *ERBB2* gene amplification, which is a well‐established class of driver gene alteration in breast and gastric cancer, protein overexpression of *NTRK* amplified tumors is inconsistent. Recently, *NTRK* amplification (copy number ≥4) was reported to result in a protein overexpression in 14.8% of patients [22](#onco13304-bib-0022){ref-type="ref"}. To our knowledge, this is the second report that describes a short but significant tumor response of larotrectinib in *NTRK* amplified tumors. Whereas larotrectinib is very specific for inhibition of TRK A, B, and C kinase domain, entrectinib is also active in *ROS1* and *ALK* fusion [21](#onco13304-bib-0021){ref-type="ref"}. The high specificity of larotrectinib for TRK A, B, C protein kinase could explain the fact that the substance seemed to be active in *NTRK* amplified cancers, whereas for entrectinib, the aforesaid efficacy was not assessed [23](#onco13304-bib-0023){ref-type="ref"}.

Conclusion {#onco13304-sec-0013}
==========

Results of the liver rebiopsy after larotrectinib failure revealed that there was a loss of the *NTRK1* amplification, hand in hand with a significant decrease of copy number of other observed genes as well. Because of the fact that the initial amplification copy number of certain genes (*EGFR* in particular, followed by *PIK3CA*, *CCND1*, *FGF19*, *FGF3*, and *FGF4*) was much higher than that of *NTRK1* (5‐ to 15‐fold), it could be speculated that some of these genes were later driving the clonal expansion of the tumor cells, influencing its possible mechanism of acquired resistance. Additionally, the mechanisms of resistance and progression in this patient may include the presence or emergence of *NTRK*‐associated coalterations, which were commonly discerned in genes that are involved in PI3K signaling, tyrosine kinase families, cell‐cycle machinery, and MAPK pathways. Additional investigation is needed to elucidate whether these genes mediate resistance to *NTRK* inhibition and if cotargeting them augments anti‐NTRK antitumor activity. This way, we could explain only the short‐lived patient\'s response to larotrectinib. In spite of finding an appropriate driver alteration, further mRNA‐based clinical studies should be conducted.

Glossary of Genomic Terms and Nomenclature {#onco13129-sec-0007}
==========================================

**NTRK1:** neurotrophic receptor tyrosine kinase 1RK

**CCND1:** cyclin D1

**CCND2:** cyclin D2

**CCND3:** cyclin D3

**EGFR:** epidermal growth factor receptor

**PIK3CA:** phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit alpha

**CDK6:** cyclin dependent kinase 6

**HGF:** hepatocyte growth factor

**SOX2:** SRY‐box transcription factor 2

**CDKN2A/B:** cyclin dependent kinase inhibitor 2A/B

**EPHB4:** ePH receptor B4

**FGF19:** fibroblast growth factor 19

**FGF3:** fibroblast growth factor 3

**FGF4:** fibroblast growth factor 4

**MCL1:** MCL1 apoptosis regulator

**PIM1:** Pim‐1 proto‐oncogene, serine/threonine Kinase

**TP53:** tumor protein P53

**VEGFA:** vascular endothelial growth factor A
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